Pancreatic hormones

Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe

Retrieved on: 
Monday, July 19, 2021

Under the terms of the applicable agreements, Xeris will be responsible for product supply and Tetris will be responsible for the commercialization of Ogluo in the Territory.

Key Points: 
  • Under the terms of the applicable agreements, Xeris will be responsible for product supply and Tetris will be responsible for the commercialization of Ogluo in the Territory.
  • Gvoke is indicated for the treatment of severe hypoglycaemia in paediatric and adult patients with diabetes ages 2 years and above.
  • The United Kingdoms Medicines and Healthcare products Regulatory Agency (MHRA) approved Ogluo (glucagon) injection on April 29, 2021.
  • Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions

Retrieved on: 
Wednesday, June 16, 2021

Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions

Key Points: 
  • Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions
    Company to present six abstracts on ZEGALOGUE(dasiglucagon) injection, including one oral presentation
    Copenhagen, DK and Boston, MA, U.S. June 16, 2021 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
  • "We are proud to share such a robust set of clinical data at this years ADA medical meeting, said Adam Steensberg, Executive Vice President, Research & Development of Zealand Pharma.
  • ZEGALOGUE is contraindicated in patients with pheochromocytoma because glucagon products may stimulate the release of catecholamines from the tumor.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines.

Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes

Retrieved on: 
Monday, March 22, 2021

ZEGALOGUE (dasiglucagon) injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.

Key Points: 
  • ZEGALOGUE (dasiglucagon) injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
  • ZEGALOGUE is contraindicated in patients with pheochromocytoma because glucagon products may stimulate the release of catecholamines from the tumor.
  • If a patient develops symptoms of hypoglycemia after a dose of ZEGALOGUE, give glucose orally or intravenously.
  • Zealand markets V-Go, a basal-bolus insulin delivery option for people with diabetes, and has received FDA approval for Zegalogue, (dasiglucagon), the first and only glucagon analogue for the treatment severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above.

ViaCyte and Gore Expand Collaboration to Develop Novel Membrane and Device Technologies that Enhance Delivery of Cell Replacement Therapies for Diabetes

Retrieved on: 
Tuesday, March 2, 2021

ViaCyte has demonstrated that when the cells successfully engraft, they produce both insulin and glucagon in T1D patients, a first in the field of cell therapy for diabetes.

Key Points: 
  • ViaCyte has demonstrated that when the cells successfully engraft, they produce both insulin and glucagon in T1D patients, a first in the field of cell therapy for diabetes.
  • ViaCyte is currently evaluating open and closed devices to deliver cell replacement therapies for type 1 diabetes (T1D) in Phase 2 clinical trials.
  • These devices contain the cell therapy while enabling oxygen and nutrients to flow into the device and insulin, glucagon, and other hormones to flow out.
  • www.gore.com
    ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation.

Altimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference

Retrieved on: 
Friday, December 11, 2020

Thedigital 4th Annual NASH Summit2020 Digital Conference is committed to delivering industry's best opportunity to gain high-quality insights and connections expected at an in-person event in a format designed to maximize knowledge-sharing and networking without the need to travel.

Key Points: 
  • Thedigital 4th Annual NASH Summit2020 Digital Conference is committed to delivering industry's best opportunity to gain high-quality insights and connections expected at an in-person event in a format designed to maximize knowledge-sharing and networking without the need to travel.
  • ALT-801 is a novel peptide-based dual GLP-1/glucagon receptor agonist that is designed to treat the obesity and metabolic dysfunction that causes NASH.
  • Altimmune believes the treatment of obesity is the cornerstone of treating NASH and the principal morbidities of NASH.
  • Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease.

CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes

Retrieved on: 
Thursday, November 5, 2020

The objective of the study is to determine if GPR119 agonists have potential to prevent hypoglycemia for people living with T1D.

Key Points: 
  • The objective of the study is to determine if GPR119 agonists have potential to prevent hypoglycemia for people living with T1D.
  • Glucagon is a hormone secreted by the pancreas, that naturally reverses hypoglycemia by signaling the body to release stored glucose.
  • In recent preclinical studies, GPR119 agonists were shown to enhance glucagon secretion in response to low glucose levels, and were able to prevent hypoglycemia in animal models.
  • Study start-up activities are underway and TRI and CymaBay will provide updates on study design, objectives and results throughout the study.